

DMD # 55228

**Journal: Drug Metabolism and Disposition**

**Title: The effect of ABCG2 and ABCC4 on the pharmacokinetics of methotrexate in brain**

**Ramola Sane, Shu-Pei Wu, Rong Zhang, James M. Gallo**

Department of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, New York, NY, USA

DMD # 55228

**Running Title:** ABCG2 and ABCC4 influence methotrexate pharmacokinetics

**Corresponding author:**

James M. Gallo

Department of Pharmacology and Systems Therapeutics, Icahn School of Medicine at Mount Sinai, Box 1603, One Gustave L. Levy Place, New York, NY 10029. Phone: 212-241-7770; Fax: 212-996-7214; E-mail: james.gallo@mssm.edu

**Manuscript statistics:**

Number of figures: 1

Number of tables: 1

Number of Pages: 20

Number of References: 35

Number of Words in Abstract: 245

Number of words in introduction: 363

Number of words in Results and Discussion: 960

**List of abbreviations:**

BBB, blood-brain-barrier; CNS, central nervous system; BCRP, breast cancer resistance protein; MRP4, multidrug resistance protein 4; LC-MS/MS, liquid chromatography-tandem mass spectrometry; AUC, area under the curve; MTX, methotrexate; 7-OH MTX, 7-hydroxy methotrexate

DMD # 55228

**Abstract:**

Methotrexate [MTX] is the cornerstone of chemotherapy for primary CNS lymphoma [PCNSL] yet how blood-brain barrier [BBB] efflux transporters ABCG2 and ABCC4 influence required high-dose therapy is unknown. To evaluate their role we used four mouse strains, C57/B6 [WT], *Abcg2*<sup>-/-</sup>, *Abcc4*<sup>-/-</sup>, and *Abcg2*<sup>-/-</sup>;*Abcc4*<sup>-/-</sup> (double knockout, DKO) and conducted brain microdialysis studies following single IV MTX doses of 50 mg/kg. Based on the  $AUC_{\text{plasma}}$  to assess systemic exposure to MTX the rank order was *Abcc4*<sup>-/-</sup> < WT < *Abcg2*<sup>-/-</sup> < *Abcg2*<sup>-/-</sup> *Abcc4*<sup>-/-</sup>, with only the DKO exposure being significantly higher than the WT group ( $p < 0.01$ ), and a reflection of role of *Abcg2* in biliary excretion and *Abcc4* in renal excretion. MTX brain interstitial fluid concentrations obtained by microdialysis were used to calculate the  $AUC_{\text{brain}}$  that found the rank order of exposure to be WT < *Abcc4*<sup>-/-</sup> < *Abcg2*<sup>-/-</sup> < *Abcg2*<sup>-/-</sup> *Abcc4*<sup>-/-</sup> with the largest difference being 4-fold;  $286.13 \pm 130 \text{ ug} \cdot \text{min/ml}$  (DKO) vs.  $66.85 \pm 26$  (WT). Since the transporters affected the systemic disposition of MTX, particularly in the DKO group, the ratio of the  $AUC_{\text{brain}}/AUC_{\text{plasma}}$  or the brain/plasma partition coefficient  $K_p$  was calculated and revealed that the double knockout strain had a significantly higher value [ $0.23 \pm 0.09$ ] than the WT strain [ $0.11 \pm 0.05$ ]. Both *Abcg2* and *Abcc4* limited BBB penetration of MTX, yet only when both drug efflux pumps were negated did the brain accumulation of MTX significantly increase. These findings indicate a contributory role of both ABCG2 and ABCC4 to limit MTX distribution in patients.

DMD # 55228

## **Introduction:**

The blood-brain barrier (BBB) is comprised of capillaries lined by endothelial cells with tight junctions to limit passive diffusion of drugs, as well as protein pumps that when directed towards the blood act as efflux transporters that limit the distribution of drugs into the central nervous system (CNS) (Deeken and Loscher, 2007). Primary BBB efflux pumps – notably *Abcb1* and *Abcg2* - are members of the ABC family of transporters and have been implicated in restricting BBB penetration of several drugs (Schinkel et al., 1996). The consequences of limited brain access for CNS-active drugs are a lower therapeutic index that could prevent use of the drug. It is essential to determine the role of the BBB and its efflux transporters in mediating the brain distribution of drugs, both to characterize mechanisms of CNS disposition and to offer a rational means to overcome limited brain distribution.

Methotrexate is the standard of care and a component of numerous experimental regimens for primary CNS lymphoma (DeAngelis, 2003; Zhu et al., 2009), a disease that accounts for 2 – 5 % of all primary brain tumors (Gerstner and Batchelor, 2007). Methotrexate (MTX) is a folate antagonist with limited uptake in brain that likely contributes to high-dose therapy (Nierenberg et al., 1991; Wolff et al., 2011). Studies in rodents (Devineni et al., 1996) and patients (Blakeley et al., 2009) that utilized brain microdialysis to measure brain interstitial fluid MTX concentrations attest to its limited distribution in normal brain with a brain-to-plasma ratio  $0.051 \pm 0.032$  and  $0.032 \pm 0.094$  in rodents and humans, respectively. MTX has been shown to be a substrate for BCRP (Volk and Schneider, 2003; Li et al., 2013) and MRP4 (Chen et al., 2002) using in vitro membrane vesicle systems. *Abcg2* has been implicated in limiting the brain distribution of several drugs (Agarwal et al., 2010; Kodaira et al., 2010; Agarwal et al., 2011) and *Abcc4* has

DMD # 55228

been shown to prevent the brain distribution of topotecan and oseltamivir (Leggas et al., 2004; Ose et al., 2009). However, the role of these transporters in limiting the distribution of MTX at the BBB has not been adequately explored, and was the subject of this investigation that utilized *Abcg2*<sup>-/-</sup>, *Abcc4*<sup>-/-</sup> and *Abcg2*<sup>-/-</sup>;*Abcc4*<sup>-/-</sup> transgenic mice. To assess the role of these transporters in the brain penetration of methotrexate we employed brain microdialysis in conjunction with serial plasma sampling following single intravenous dose administrations.

### **Materials and Methods:**

Methotrexate hydrate (Molecular weight: 454.44), 7-hydroxy methotrexate (molecular weight: 470.44) and aminopterin were purchased from Sigma-Aldrich (St. Louis, MO). All other chemicals were reagent grade or HPLC grade and purchased from Sigma-Aldrich. Guide cannulas (5 mm shaft) and MetaQuant probes (regenerated cellulose, dialysis tip length 2 mm, MW cut-off 13 kDa) were purchased from Brainlink (Groningen, The Netherlands).

### **Animals:**

C57BL wild-type and transgenic mice with genetic deletions of either the *Abcg2* transporter (*Abcg2* knockout, *Abcg2*<sup>-/-</sup>), *Abcc4* transporter (*Abcc4* knockout, *Abcc4*<sup>-/-</sup>) or both transporters (double knockout or DKO, *Abcg2*<sup>-/-</sup>;*Abcc4*<sup>-/-</sup>) were derived in the laboratory of Dr. Gary Kruh (deceased) (Belinsky et al., 2007; Wang et al., 2011)- previously at Fox Chase Cancer Center and lastly at the University of Illinois – Chicago - and then transferred and maintained at Charles River Inc (Wilmington, MA) through an agreement with Mount Sinai School of Medicine. Mice were transferred to Mount Sinai approximately 7 days prior to entry into the pharmacokinetic studies and were maintained at a 12 hour light/dark cycle with unlimited access to food and water. All animal studies were approved by the Institutional Animal Care and Use committee at

DMD # 55228

Mount Sinai School of Medicine (IACUC). All mice used in the experiment were male and 10-12 weeks of age and weighed 25-30g.

### **Microdialysis preparation:**

Anesthetized mice underwent a surgical microdialysis and vascular cannula implantation procedure as previously described (Guo et al., 2007) three days prior to the pharmacokinetic study with the modification that a Meta-Quant probe system was used and located at 0.74 mm anterior and 2.0 mm lateral to the bregma with the guide cannula lowered to a depth of 2.5 mm. The Meta-Quant microdialysis system is designed to increase analyte recovery by perfusion of the dialysis membrane at a low flow rate (0.1  $\mu\text{L}/\text{min}$ ) whilst simultaneously using a higher make-up flow rate (0.9  $\mu\text{L}/\text{min}$ ) to eliminate long sample collection periods (Cremers et al., 2009). Animals were then placed on a heating pad during recovery and then when fully ambulatory provided food and water ad libitum with food being removed 2 hours prior to the pharmacokinetic study. The guide cannulas were replaced by the microdialysis probes and calibrated by a retrodialysis method and the recovery calculated as previously described (Guo et al., 2007). At the completion of the retrodialysis calibration the animals were administered a dose of 50 mg/kg methotrexate hydrate as an IV bolus through a tail vein. Serial dialysate (~20  $\mu\text{L}$ ) samples were collected every 20 min up to 8 hours post-dose using a refrigerated sample collector (CMA 470, Harvard Apparatus, Massachusetts) and stored directly at  $-80^{\circ}\text{C}$  until analysis. Serial blood samples of 20  $\mu\text{L}$  were collected at 5 min, 15 min, 30 min, 1 hr, 2 hr, 3 hr, 4 hr, 6 hr and 8 hours post-dose. Saline (10  $\mu\text{L}$ ) was injected through the carotid artery cannula to avoid volume depletion. The samples were then centrifuged, and the resultant plasma was stored at  $-80^{\circ}\text{C}$  until analyzed by liquid chromatography/tandem mass spectrometry (LC/MS/MS) according to a previously published method (Guo et al., 2007).

DMD # 55228

Sample preparation was carried out as described before (Guo et al., 2007). Two  $\mu\text{L}$  of plasma and 10  $\mu\text{l}$  of brain dialysate, were precipitated with 20  $\mu\text{L}$  of acetonitrile and used for quantification. The method was modified by changing the flow rate on the HPLC as follows: A mobile phase of 0.5 mM ammonium formate with 0.1% formic acid and acetonitrile using gradient elution, 2% acetonitrile for the first 0.5 min, followed by 80% acetonitrile from 0.8 to 2min and then back to 2% from 2.5 min to 7 min at a flow rate of 0.3 ml/min.

### **Data analysis:**

Noncompartmental analysis was carried out on the both the plasma and brain concentration – time profiles for each mouse in all four genotypes using Kinectica (Version 5.1, Thermo Fisher Scientific, Pittsburgh, PA). The terminal rate constants were calculated using the data points that best described the terminal elimination phase. The areas under the concentration-time curve for plasma ( $\text{AUC}_{\text{plasma}}$ ) and brain ( $\text{AUC}_{\text{brain}}$ ), from time 0 to infinity were calculated using the log-linear method with the AUC from last measured time point to infinity estimated by dividing the last measured concentration by the elimination rate constant. In all cases, the contribution of the extrapolated AUC to the time infinity values was 8% or less. The brain-to-plasma partition coefficient ( $K_{p,\text{brain}}$ ) of methotrexate was calculated as a ratio of  $\text{AUC}_{\text{brain}}/\text{AUC}_{\text{plasma}}$ .

### **Statistical analysis:**

GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA) was used to determine differences between genotypes by non-parametric one-way analysis of variance (ANOVA) using a Kruskal-Wallis test followed by a Dunns post-test to compare between strains such that a p-value less than 0.05 is indicative of significance.

### **Results and Discussion:**

DMD # 55228

Given the extensive use of methotrexate in the treatment of primary and secondary CNS tumors, it is essential that the role of BBB in limiting its brain distribution be examined in detail.

However in doing so it is important to also evaluate the influence of the transporters on the systemic disposition of methotrexate by assessing changes in drug clearance since clearance – the inverse of the AUC - will determine plasma drug concentrations and influence tissue distribution. Both the *Abcg2*<sup>-/-</sup> and *Abcg2*<sup>-/-</sup>*Abcc4*<sup>-/-</sup> strains had reduced total clearance values (**Table 1, Figure 1 A**) compared to the wild-type and the *Abcc4*<sup>-/-</sup> mice; however only the DKO strain reached statistical significance being 2-fold lower than the wild-type strain (p= 0.004). The absence of *Abcc4* did not alter the clearance of MTX in mice (Kitamura et al., 2008) consistent with our results, and indicates the reduction in total clearance in the DKO strain is largely due to reduced biliary clearance - a major route of elimination of MTX in rodents (Bremnes et al., 1989) - and the lack of *Abcg2* on bile canaliculi (Zamek-Gliszczynski et al., 2006). Nonetheless, a role for *Abcc4* in the renal clearance of methotrexate could be inferred since the total clearance in the DKO was quite a bit lower than the single *Abcg2* knockout strain. This potential role of MRP4 – localized to the renal proximal tubule (van Aubel et al., 2002) - could be more important in humans where renal clearance of methotrexate is dominant.

The AUC for the 7-hydroxy metabolite of methotrexate was higher in *Abcg2*<sup>-/-</sup> and reached statistical significance in *Abcg2*<sup>-/-</sup>*Abcc4*<sup>-/-</sup> groups ( $59.9 \pm 23.7$  and  $81.5 \pm 23.9$   $\mu\text{g} \cdot \text{min}/\text{ml}$ , respectively, p= 0.0022) as compared to the wild-type mice ( $26.13 \pm 8.7$   $\mu\text{g} \cdot \text{min}/\text{ml}$ ); consistent with the work of Vlaming et.al. in *Abcg2*<sup>-/-</sup> mice that concluded that the increased  $\text{AUC}_{7\text{-OHMTX}}$  is likely due to enhanced retention of MTX in the liver (Vlaming et al., 2009) and its subsequent metabolism rather than any transporter effect on the metabolite.



DMD # 55228

BCRP and MRP4 are among the most highly expressed transport proteins at the mouse and human BBB (Carl et al., 2010; Agarwal et al., 2012). Unbound brain concentrations and not total brain concentrations are indicative of interactions with target receptors and determines CNS efficacy (Liu et al., 2009). Therefore, since brain microdialysis provides a measure of the unbound drug concentration it is the ideal technique to indicate the amount of drug available to the intracellular compartment for drug-receptor binding as well as to indicate the influence of drug efflux pumps at the BBB.

The brain concentrations in the DKO mice were higher than that observed in the wild-type and either single knockout mice (**Figure 1 B**) that yielded corresponding changes in the  $AUC_{\text{brain}}$  (see **Table 1**). However, to accurately assess the role of the transporters on regional brain distribution it is important to use the brain partition coefficient ( $K_p$ ) – the ratio  $AUC_{\text{brain}}/AUC_{\text{plasma}}$  – that accounts for changes in the systemic exposure of MTX. Specifically, the brain partition coefficient was 2-fold greater ( $K_p = 0.23 \pm 0.09$ , see Table 1) in the DKO compared to the WT strain ( $K_p = 0.11 \pm 0.05$ ), which represented the largest difference amongst all strains ( $p$  value = 0.017) (**Figure 2**). The brain partition coefficient in *Abcg2* knockouts ( $0.17 \pm 0.08$ ) was not significantly different from that in wild-type mice ( $0.11 \pm 0.05$ ) and partially reflects the increased plasma exposure. On the other hand, the  $K_p$  in *Abcc4* knockout mice ( $0.19 \pm 0.09$ ), while not statistically different from the WT strain, and analogous to that in the *Abcg2* knockout mice suggests a local BBB effect due to deletion of the transporter, since the  $AUC_{\text{plasma}}$  values in *Abcc4* knockout and wild-type groups are virtually identical. MTX is a low affinity substrate for human BCRP, having a  $K_m$  of about 680  $\mu\text{M}$  to 1.3 mM (Chen et al., 2003; Volk and Schneider, 2003), compared to 220  $\mu\text{M}$  for human MRP4 (Chen et al., 2002); as determined by in vitro studies. The expression of BCRP is almost 2-fold higher than MRP4 at the mouse BBB (Agarwal

DMD # 55228

et al., 2012) and nearly 40-fold higher in humans (Uchida et al., 2011). If we assume that the transporter affinity ( $K_m$ ) for MTX in mice is similar to the in vitro values, and that the expression of the transporters at the BBB is reflective of the  $V_{max}$  for the respective transporters; the clearance out of the brain (ratio of  $V_{max}$  to  $K_m$ , assuming linearity), for both transporters could be comparable. Although this extrapolation is speculative it could explain why the single deletion of either Bcrp or Mrp4 has nearly similar effects on the brain distribution of MTX. Not unexpectedly, the simultaneous absence of Abcg2 and Abcc4, the DKO strain, caused the greatest increase in the  $K_p$  values of MTX, and supports the cooperative action of these transporters at the BBB. A similar study with topotecan also revealed the cooperative behavior of MRP4 with BCRP and P-gp at the mouse BBB (Lin et al., 2013).

In this study, we show conclusively, that the brain exposure of MTX is limited by efflux due to BCRP and MRP4 in a cooperative manner. This is an important effect to be considered, as MTX is a standard of care in primary CNS lymphoma, as well as in metastatic brain tumors (Lassman et al., 2006; Jacot et al., 2010). While breakdown of the BBB in a tumor can result in higher brain concentration of MTX (Blakeley et al., 2009); many brain tumors are invasive and diffuse, and exist behind an intact BBB (DeAngelis, 2003). The results from this study reinforce the idea that the BBB and the transporters at the BBB play an important role in the disposition of methotrexate and that its efficacy could be limited by their presence.

DMD # 55228

## **Authorship Contributions**

*Participated in research design:* Wu, Gallo

*Conducted experiments:* Wu, Zhang

*Contributed new reagents or analytic tools:* Zhang, Wu

*Performed data analysis:* Sane, Gallo

*Wrote or contributed to the writing of the manuscript:* Sane, Gallo

DMD # 55228

## References :

- Agarwal S, Sane R, Gallardo JL, Ohlfest JR, and Elmquist WF (2010) Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. *J Pharmacol Exp Ther* **334**:147-155.
- Agarwal S, Sane R, Ohlfest JR, and Elmquist WF (2011) The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. *J Pharmacol Exp Ther* **336**:223-233.
- Agarwal S, Uchida Y, Mittapalli RK, Sane R, Terasaki T, and Elmquist WF (2012) Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout mice. *Drug Metab Dispos* **40**:1164-1169.
- Belinsky MG, Guo P, Lee K, Zhou F, Kotova E, Grinberg A, Westphal H, Shchhaveleva I, Klein-Szanto A, Gallo JM, and Kruh GD (2007) Multidrug resistance protein 4 protects bone marrow, thymus, spleen, and intestine from nucleotide analogue-induced damage. *Cancer Res* **67**:262-268.
- Blakeley JO, Olson J, Grossman SA, He X, Weingart J, and Supko JG (2009) Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis study. *J Neurooncol* **91**:51-58.
- Bremnes RM, Slordal L, Wist E, and Aarbakke J (1989) Dose-dependent pharmacokinetics of methotrexate and 7-hydroxymethotrexate in the rat in vivo. *Cancer Res* **49**:6359-6364.
- Carl SM, Lindley DJ, Couraud PO, Weksler BB, Romero I, Mowery SA, and Knipp GT (2010) ABC and SLC transporter expression and pot substrate characterization across the human CMEC/D3 blood-brain barrier cell line. *Mol Pharm* **7**:1057-1068.

DMD # 55228

Chen ZS, Lee K, Walther S, Raftogianis RB, Kuwano M, Zeng H, and Kruh GD (2002) Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. *Cancer Res* **62**:3144-3150.

Chen ZS, Robey RW, Belinsky MG, Shchaveleva I, Ren XQ, Sugimoto Y, Ross DD, Bates SE, and Kruh GD (2003) Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. *Cancer Res* **63**:4048-4054.

Cremers TI, de Vries MG, Huinink KD, van Loon JP, v d Hart M, Ebert B, Westerink BH, and De Lange EC (2009) Quantitative microdialysis using modified ultraslow microdialysis: direct rapid and reliable determination of free brain concentrations with the MetaQuant technique. *J Neurosci Methods* **178**:249-254.

DeAngelis LM (2003) Primary central nervous system lymphoma: a curable brain tumor. *J Clin Oncol* **21**:4471-4473.

Deeken JF and Loscher W (2007) The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. *Clin Cancer Res* **13**:1663-1674.

Devineni D, Klein-Szanto A, and Gallo JM (1996) In vivo microdialysis to characterize drug transport in brain tumors: analysis of methotrexate uptake in rat glioma-2 (RG-2)-bearing rats. *Cancer Chemother Pharmacol* **38**:499-507.

Gerstner E and Batchelor T (2007) Primary CNS lymphoma. *Expert Rev Anticancer Ther* **7**:689-700.

Guo P, Wang X, Liu L, Belinsky MG, Kruh GD, and Gallo JM (2007) Determination of methotrexate and its major metabolite 7-hydroxymethotrexate in mouse plasma and brain

DMD # 55228

tissue by liquid chromatography-tandem mass spectrometry. *J Pharm Biomed Anal* **43**:1789-1795.

Jacot W, Gerlotto-Borne MC, Thezenas S, Poudroux S, Poujol S, About M, and Romieu G (2010) Carmustine and methotrexate in combination after whole brain radiation therapy in breast cancer patients presenting with brain metastases: a retrospective study. *BMC Cancer* **10**:257.

Kitamura Y, Hirouchi M, Kusuhara H, Schuetz JD, and Sugiyama Y (2008) Increasing systemic exposure of methotrexate by active efflux mediated by multidrug resistance-associated protein 3 (mrp3/abcc3). *J Pharmacol Exp Ther* **327**:465-473.

Kodaira H, Kusuhara H, Ushiki J, Fuse E, and Sugiyama Y (2010) Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone. *J Pharmacol Exp Ther* **333**:788-796.

Lassman AB, Abrey LE, Shah GD, Panageas KS, Begemann M, Malkin MG, and Raizer JJ (2006) Systemic high-dose intravenous methotrexate for central nervous system metastases. *J Neurooncol* **78**:255-260.

Leggas M, Adachi M, Scheffer GL, Sun D, Wielinga P, Du G, Mercer KE, Zhuang Y, Panetta JC, Johnston B, Scheper RJ, Stewart CF, and Schuetz JD (2004) Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. *Mol Cell Biol* **24**:7612-7621.

Li L, Agarwal S, and Elmquist WF (2013) Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate. *Drug Metab Dispos* **41**:659-667.

DMD # 55228

Lin F, Marchetti S, Pluim D, Iusuf D, Mazzanti R, Schellens JH, Beijnen JH, and van Tellingen

O (2013) Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues. *Clin Cancer Res* **19**:2084-2095.

Liu X, Vilenski O, Kwan J, Apparsundaram S, and Weikert R (2009) Unbound brain concentration determines receptor occupancy: a correlation of drug concentration and brain serotonin and dopamine reuptake transporter occupancy for eighteen compounds in rats. *Drug Metab Dispos* **37**:1548-1556.

Nierenberg D, Harbaugh R, Maurer LH, Reeder T, Scott G, Fratkin J, and Newman E (1991) Continuous intratumoral infusion of methotrexate for recurrent glioblastoma: a pilot study. *Neurosurgery* **28**:752-761.

Ose A, Ito M, Kusuhara H, Yamatsugu K, Kanai M, Shibasaki M, Hosokawa M, Schuetz JD, and Sugiyama Y (2009) Limited brain distribution of [3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 64-0802), a pharmacologically active form of oseltamivir, by active efflux across the blood-brain barrier mediated by organic anion transporter 3 (Oat3/Slc22a8) and multidrug resistance-associated protein 4 (Mrp4/Abcc4). *Drug Metab Dispos* **37**:315-321.

Schinkel AH, Wagenaar E, Mol CA, and van Deemter L (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. *J Clin Invest* **97**:2517-2524.

Uchida Y, Ohtsuki S, Katsukura Y, Ikeda C, Suzuki T, Kamiie J, and Terasaki T (2011) Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. *J Neurochem* **117**:333-345.

DMD # 55228

- van Aubel RA, Smeets PH, Peters JG, Bindels RJ, and Russel FG (2002) The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. *J Am Soc Nephrol* **13**:595-603.
- Vlaming ML, van Esch A, Pala Z, Wagenaar E, van de Wetering K, van Tellingen O, and Schinkel AH (2009) Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo. *Mol Cancer Ther* **8**:3350-3359.
- Volk EL and Schneider E (2003) Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. *Cancer Res* **63**:5538-5543.
- Wang Z, Zhou Q, Kruh GD, and Gallo JM (2011) Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. *Drug Metab Dispos* **39**:2155-2161.
- Wolff JE, Kortmann RD, Wolff B, Pietsch T, Peters O, Schmid HJ, Rutkowski S, Warmuth-Metz M, and Kramm C (2011) High dose methotrexate for pediatric high grade glioma: results of the HIT-GBM-D pilot study. *J Neurooncol* **102**:433-442.
- Zamek-Gliszczyński MJ, Nezasa K, Tian X, Kalvass JC, Patel NJ, Raub TJ, and Brouwer KL (2006) The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice. *Mol Pharmacol* **70**:2127-2133.
- Zhu JJ, Gerstner ER, Engler DA, Mrugala MM, Nugent W, Nierenberg K, Hochberg FH, Betensky RA, and Batchelor TT (2009) High-dose methotrexate for elderly patients with primary CNS lymphoma. *Neuro Oncol* **11**:211-215.



DMD # 55228

## **Footnotes**

This work was supported by the National Institute of Health Cancer Institute [Grant CA073728].

DMD # 55228

### Figure Legends:



**Figure 1:** (A) Plasma concentrations of methotrexate in wild-type, *Abcg2*<sup>-/-</sup>, *Abcc4*<sup>-/-</sup>, and *Abcg2*<sup>-/-</sup>*Abcc4*<sup>-/-</sup> mice following a 50 mg/kg dose of methotrexate hydrate intravenously. Mean  $\pm$  SD (n=4 or n=5). Plasma concentrations in the *Abcg2*<sup>-/-</sup>*Abcc4*<sup>-/-</sup> mice are consistently higher than those observed in wild-type (B) Corresponding brain concentrations of methotrexate in wild-type, *Abcg2*<sup>-/-</sup>, *Abcc4*<sup>-/-</sup>, and *Abcg2*<sup>-/-</sup>*Abcc4*<sup>-/-</sup> mice following a 50 mg/kg dose of methotrexate hydrate intravenously. Mean  $\pm$  SD (n=4 or n=5). Brain concentrations in the *Abcg2*<sup>-/-</sup> and *Abcg2*<sup>-/-</sup>*Abcc4*<sup>-/-</sup> mice are higher than those observed in wild-type

**Figure 2:** The partition coefficient for methotrexate in the brain ( $K_{p,brain}$ ) in wild-type, *Abcg2*<sup>-/-</sup>, *Abcc4*<sup>-/-</sup>, and *Abcg2*<sup>-/-</sup>*Abcc4*<sup>-/-</sup> mice.  $K_{p,brain}$  in *Abcc4*<sup>-/-</sup>, *Abcg2*<sup>-/-</sup> mice is two-fold higher than in the wild-type mice(\*, p<0.05)

**Table 1:** Pharmacokinetic parameters in the plasma for MTX and 7-OH MTX and for MTX in the brain determined by noncompartmental analysis after a 50 mg/kg intravenous bolus dose of methotrexate in wild-type, *Abcg2*<sup>-/-</sup>, *Abcc4*<sup>-/-</sup> and *Abcg2*<sup>-/-</sup>*Abcc4*<sup>-/-</sup> mice (\*p<0.05, \*\* p<0.01).

	Parameters	units	Wild-type	<i>Abcg2</i> <sup>-/-</sup>	<i>Abcc4</i> <sup>-/-</sup>	<i>Abcg2</i> <sup>-/-</sup> ; <i>Abcc4</i> <sup>-/-</sup>
			n=6	n=5	n=5	n=6
PLASMA	CL	ml/min	1.96 ± 0.38	1.58 ± 0.52	2.00 ± 0.40	1.00 ± 0.20*
	Vd	L	0.54 ± 0.40	0.28 ± 0.14	0.73 ± 0.29	0.18 ± 0.09 *
	Half-life <sub>(MTX<sub>plasma</sub>)</sub>	min	195 ± 171	124 ± 28	247 ± 81	116 ± 28*
	AUC <sub>MTX(0-inf)</sub>	min*ug/ml	633 ± 121	836.9 ± 208	631 ± 185	1259 ± 289**
	AUC <sub>7-OH-MTX(0-inf)</sub>	min*ug/ml	26.1 ± 8.7	59.9 ± 23.7	22.2 ± 6.2	81.5 ± 23.9**
	Half-life <sub>7OH-MTX</sub>	min	224 ± 131	237 ± 74.7	242 ± 96	200 ± 74
	AUC <sub>7OH/AUC<sub>MTX</sub>%</sub>		4.16 ± 1.35	7.80 ± 1.59	3.55 ± 0.6	6.52 ± 1.10
BRAIN	AUC <sub>brain</sub>	min*ug/ml	66.85 ± 26	134 ± 54.80	118.12 ± 60.50	286.13 ± 130**
	Half-life <sub>brain</sub>	min	151 ± 69	104 ± 44	62.3 ± 22.7	88 ± 15
	C <sub>max</sub>	ug/ml	1.2 ± 0.5	1.8 ± 0.9	1.5 ± 0.6	3.7 ± 2.2
	K <sub>p,brain</sub>		0.11 ± 0.05	0.17 ± 0.08	0.19 ± 0.09	0.23 ± 0.09*

# Figure 1



# Figure 2

